ClearPoint Neuro Reports First Quarter 2024 Results
ClearPoint Neuro Reports First Quarter 2024 Results
ClearPoint Neuro Reports First Quarter 2024 Results
ClearPoint Neuro公佈2024年第一季度業績
May 07, 2024 4:05pm EDT Download as PDF
美國東部時間 2024 年 5 月 7 日下午 4:05 以 PDF 格式下載
First Quarter Revenue Growth +41%; Record Revenue Achieved
第一季度收入增長+41％；實現創紀錄的收入
SOLANA BEACH, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its first quarter ended March 31, 2024.
加利福尼亞州索拉納海灘，2024年5月7日（GLOBE NEWSWIRE）——提供大腦和脊柱精確導航的全球設備、細胞和基因療法支持公司ClearPoint Neuro, Inc.（納斯達克股票代碼：CLPT）（“公司”）今天公佈了截至2024年3月31日的第一季度財務業績。
First Quarter Highlights
第一季度亮點
- Reported quarterly revenue of $7.6 million, a 41% year-over-year increase;
- Increased biologics and drug delivery revenue to $4.3 million, a 61% year-over-year increase;
- Partner PTC Therapeutics submitted first-ever neuro gene therapy BLA to the FDA;
- Received 510(k) clearance for SmartFrame OR Stereotactic System to support expansion into the Operating Room and performed first clinical cases;
- Activated eight new hospital customers in the first quarter, a new Company record for a quarter and bringing our total number of global centers to over 80 sites;
- Operational cash burn reduced to $3.8 million, a 32% year-over-year decrease;
- Completed a public offering of common stock, resulting in net proceeds of approximately $16.2 million;
- Cash and cash equivalents totaled $35.4 million as of March 31, 2024.
- 報告的季度收入爲760萬美元，同比增長41％；
- 生物製劑和藥物遞送收入增加到430萬美元，同比增長61％；
- 合作伙伴PTC Therapeutics向美國食品藥品管理局提交了有史以來第一份神經基因療法BLA；
- 獲得了 SmartFrame OR 的 510 (k) 個許可 立體定位系統支持手術室的擴建和首批臨床病例；
- 第一季度激活了八個新醫院客戶，創下了公司一個季度的新紀錄，使我們的全球中心總數達到80多個地點；
- 運營現金消耗減少至380萬美元，同比下降32％；
- 完成普通股的公開發行，淨收益約爲1,620萬美元；
- 截至2024年3月31日，現金及現金等價物總額爲3540萬美元。
"Our ClearPoint Neuro team enjoyed the best operating performance in our Company's history, with contributions coming from all four of our growth pillars," commented Joe Burnett, President and CEO at ClearPoint Neuro. "Overall, the company achieved record revenue of $7.6 million or 41% growth, led by 61% growth in biologics and drug delivery revenue, and 255% growth in capital sales and service, which were also both new records. We were thrilled to see not only over 60% growth in the core biologics business, but to see many of our partners progress from a regulatory standpoint including the first neuro gene therapy BLA ever submitted to the FDA, and first patient enrolled in multiple partner IDE trials since the start of the year."
ClearPoint Neuro總裁兼首席執行官喬·伯內特評論說：“我們的ClearPoint Neuro團隊創下了公司歷史上最好的經營業績，其貢獻來自我們的所有四個增長支柱。”“總體而言，該公司實現了創紀錄的760萬美元收入，增長了41％，其中生物製劑和藥物遞送收入增長了61％，資本銷售和服務增長了255％，這也是新紀錄。我們很高興看到核心生物製劑業務的增長不僅超過60％，而且看到我們的許多合作伙伴從監管角度取得進展，包括有史以來向FDA提交的第一份神經基因療法BLA，以及自年初以來首次註冊參與多個合作伙伴IDE試驗的患者。”
"Our device business activated eight new sites in the quarter," continued Burnett, "which was our fastest activation period ever. For perspective, historically our Company would activate about eight new customers in a calendar year, and here we activated eight in the first quarter alone, with a very healthy funnel of additional activations expected this year. These new sites are going through training and are expected to support our case volume and disposable revenue growth starting in the second quarter, both using our legacy MRI guided navigation system as well as our new FDA cleared Operating Room Navigation system, the SmartFrame OR, for which we initiated a limited market release in Q1 and successfully performed our initial clinical cases. We have also placed multiple new Prism laser therapy systems and so far this year released a new software version to improve workflow and performance. We also achieved FDA clearance of a key ancillary bone anchor which will facilitate laser applicators being placed not only with ClearPoint navigation, but with other common operating room navigation and robotic systems. ClearPoint Neuro's first quarter accomplishments were achieved while keeping our operating expenses relatively flat year over year and reducing our operational cash burn by more than 30%. Our successful capital raise of $16.2 million in net proceeds not only brought new institutional investors into our Company, but also solidified our balance sheet with $35.4 million in cash and cash equivalents at the end of the quarter. The team is excited to have started 2024 off strong with many more important milestones expected this year."
伯內特繼續說：“我們的設備業務在本季度激活了八個新站點，這是我們有史以來最快的激活期。從長遠來看，我們公司將在一個日曆年內激活大約八個新客戶，而僅在第一季度我們就激活了八個新客戶，預計今年還會有非常不錯的額外激活渠道。這些新機構正在接受培訓，預計將從第二季度開始支持我們的病例數量和可支配收入的增長，這兩個系統均使用我們傳統的核磁共振成像制導導航系統以及經美國食品藥品管理局批准的新手術室導航系統SmartFrame OR，我們在第一季度啓動了限量上市併成功進行了初步臨床病例。我們還部署了多個新的Prism激光治療系統，今年到目前爲止，我們還發布了新的軟件版本，以改善工作流程和性能。我們還獲得了美國食品藥品管理局對關鍵輔助骨錨的批准，這將有助於放置激光塗抹器，不僅可以通過 ClearPoint 導航，還可以與其他常見的手術室導航和機器人系統一起放置。ClearPoint Neuro在第一季度取得的成就的同時，我們的運營支出同比保持相對平穩，運營現金消耗減少了30％以上。我們成功籌集了1,620萬澳元的淨收益，這不僅爲我們公司帶來了新的機構投資者，而且在本季度末以3540萬美元的現金和現金等價物鞏固了我們的資產負債表。該團隊很高興在2024年開局表現強勁，預計今年還會有更多重要的里程碑。”
Business Outlook
商業展望
The Company reaffirms its full year 2024 revenue outlook of between $28.0 and $32.0 million.
該公司重申其2024年全年收入展望在2,800萬美元至3,200萬美元之間。
Financial Results – Quarter Ended March 31, 2024
財務業績——截至2024年3月31日的季度
Total revenue was $7.6 million for the three months ended March 31, 2024, and $5.4 million for the three months ended March 31, 2023, which represents an increase of $2.2 million, or 41%.
截至2024年3月31日的三個月，總收入爲760萬美元，截至2023年3月31日的三個月，總收入爲540萬美元，增長了220萬美元，增長了41％。
Biologics and drug delivery revenue, which includes sales of disposable products and services related to customer-sponsored pre-clinical and clinical trials utilizing our products, increased 61% to $4.3 million for the three months ended March 31, 2024, from $2.7 million for the same period in 2023.
截至2024年3月31日的三個月，生物製劑和藥物遞送收入，包括與客戶贊助的使用我們產品的臨床前和臨床試驗相關的一次性產品和服務的銷售，從2023年同期的270萬美元增長了61％，至430萬美元。
Functional neurosurgery navigation and therapy revenue, decreased 18% to $1.9 million for the three months ended March 31, 2024, from $2.4 million for the same period in 2023. The decrease is driven primarily by lower service revenue of $0.5 million as a result of pausing a co-development program with one of our Brain Computer Interface partners.
功能性神經外科導航和治療收入從2023年同期的240萬美元下降了18％，至截至2024年3月31日的三個月的190萬美元。下降的主要原因是暫停了與我們的一個大腦計算機接口合作伙伴的共同開發計劃，導致服務收入減少了50萬美元。
Capital equipment and software revenue, consisting of sales of ClearPoint reusable hardware and software, and of related services, increased 255% to $1.4 million for the three months ended March 31, 2024, from $0.4 million for the same period in 2023 due to a large increase in the placements of ClearPoint navigation capital and software and Prism laser units.
資本設備和軟件收入，包括ClearPoint可重複使用的硬件和軟件以及相關服務的銷售，從2023年同期的40萬美元增長了255％，至140萬美元，這要歸因於ClearPoint導航資本和軟件以及Prism激光裝置的投放量大幅增加。
Gross margin for the three months ended March 31, 2024, was 59%, in line with gross margin of 59% for the three months ended March 31, 2023.
截至2024年3月31日的三個月，毛利率爲59％，與截至2023年3月31日的三個月的毛利率爲59％。
Operating expenses for the first quarter of 2024 were $8.8 million, compared to $8.9 million for the first quarter of 2023. The decrease was mainly driven by lower product development costs and bad debt expense, partially offset by higher sales and marketing personnel expense.
2024年第一季度的運營支出爲880萬美元，而2023年第一季度的運營支出爲890萬美元。下降的主要原因是產品開發成本和壞賬支出降低，部分被銷售和營銷人員支出的增加所抵消。
At March 31, 2024, the Company had cash and cash equivalents totaling $35.4 million as compared to $23.1 million at December 31, 2023, with the increase resulting from the net proceeds from the public offering of common stock of $16.2 million, partially offset by the use of cash in operating activities of $3.8 million.
截至2024年3月31日，該公司的現金及現金等價物總額爲3540萬美元，而截至2023年12月31日爲2310萬美元，這一增長來自普通股公開發行淨收益1,620萬美元，部分被經營活動中使用的現金380萬美元所抵消。
Teleconference Information
電話會議信息
Investors and analysts are invited to listen to a live broadcast review of the Company's 2024 first quarter on Tuesday, May 7, 2024 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here: https://event.choruscall.com/mediaframe/webcast.html?webcastid=8hsthhLn. Investors and analysts who would like to participate in the conference call via telephone may do so at (877) 407-9034, or at (201) 493-6737 if calling from outside the U.S. or Canada.
邀請投資者和分析師於美國東部時間2024年5月7日星期二下午4點30分（太平洋時間下午1點30分）收聽公司2024年第一季度的直播回顧，該評論可在此處在線觀看：https://event.choruscall.com/mediaframe/webcast.html?webcastid=8hsthhLn。想通過電話參加電話會議的投資者和分析師可以撥打 (877) 407-9034，如果來自美國或加拿大以外的國家，則可致電 (201) 493-6737。
For those who cannot access the live broadcast, a replay will be available shortly after the completion of the call until June 7, 2024, by calling (877) 660-6853 or (201) 612-7415 if calling from outside the U.S. or Canada, and then entering conference I.D. number 413671. An online archive of the broadcast will be available on the Company's Investor website at https://ir.clearpointneuro.com/.
對於那些無法觀看直播的人，將在電話會議結束後不久進行重播，直至2024年6月7日，如果從美國或加拿大境外撥打電話，請致電（877）660-6853或（201）612-7415，然後輸入會議身份證號碼413671。該廣播的在線檔案將在公司的投資者網站上公佈，網址爲 https://ir.clearpointneuro.com/。
About ClearPoint Neuro
ClearPoint Neuro
ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company uniquely provides both established clinical products as well as pre-clinical development services for controlled drug and device delivery. The Company's flagship product, the ClearPoint Neuro Navigation System, has FDA clearance and is CE-marked. ClearPoint Neuro is engaged with healthcare and research centers in North America, Europe, Asia, and South America. The Company is also partnered with the most innovative pharmaceutical/biotech companies, academic centers, and contract research organizations, providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide. To date, thousands of procedures have been performed and supported by the Company's field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit www.clearpointneuro.com.
ClearPoint Neuro是一家支持設備、細胞和基因療法的公司，爲大腦和脊柱提供精確導航。該公司以獨特的方式爲受控藥物和器械交付提供成熟的臨床產品和臨床前開發服務。該公司的旗艦產品ClearPoint神經導航系統已獲得美國食品藥品管理局的許可，並獲得了CE認證。ClearPoint Neuro與北美、歐洲、亞洲和南美的醫療保健和研究中心合作。該公司還與最具創新性的製藥/生物技術公司、學術中心和合同研究組織合作，爲全球臨床前研究和臨床試驗中直接提供中樞神經系統療法的解決方案。迄今爲止，公司的現場臨床專家團隊已經進行了數千例手術並提供了支持，該團隊爲我們在全球的客戶和合作夥伴提供支持和服務。欲了解更多信息，請訪問 www.clearpointneuro.com。
Forward-Looking Statements
前瞻性陳述
Statements in this press release and in the teleconference referenced above concerning the Company's plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, the size of total addressable markets or the market opportunity for the Company's products and services, the Company's expectation for revenues, operating expenses, the adequacy of cash and cash equivalent balances to support operations and meet future obligations, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. These forward-looking statements are based on management's current expectations and are subject to the risks inherent in the business, which may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: global and political instability, supply chain disruptions, labor shortages, and macroeconomic and inflationary conditions; future revenue from sales of the Company's products and services; the Company's ability to market, commercialize and achieve broader market acceptance for new products and services offered by the Company; the ability of our biologics and drug delivery partners to achieve commercial success, including their use of the Company's products and services in their delivery of therapies; the Company's expectations, projections and estimates regarding expenses, future revenue, capital requirements, and the availability of and the need for additional financing; the Company's ability to obtain additional funding to support its research and development programs; the ability of the Company to manage the growth of its business; the Company's ability to attract and retain its key employees; and risks inherent in the research, development, and regulatory approval of new products. More detailed information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, which has been filed with the Securities and Exchange Commission, and the Company's Quarterly Report on Form 10-Q for the three months ended March 31, 2024, which the Company intends to file with the Securities and Exchange Commission on or before May 15, 2024. The Company does not assume any obligation to update these forward-looking statements.
本新聞稿和上述電話會議中有關公司計劃、增長和戰略的聲明可能包括聯邦證券法背景下的前瞻性陳述。根據這些法律的定義，有關公司未來事件、發展和未來業績、總潛在市場規模或公司產品和服務的市場機會、公司對收入、運營支出、支持運營和履行未來義務的現金和現金等價物餘額的充足性，以及管理層對未來的預期、信念、計劃、估計或預測的陳述均爲前瞻性陳述。這些前瞻性陳述基於管理層當前的預期，受業務固有風險的影響，這可能導致公司的實際業績與前瞻性陳述中表達或暗示的業績存在重大差異。特定的不確定性和風險包括：全球和政治不穩定、供應鏈中斷、勞動力短缺以及宏觀經濟和通貨膨脹狀況；公司產品和服務銷售的未來收入；公司對公司提供的新產品和服務進行營銷、商業化和獲得更廣泛市場接受的能力；我們的生物製劑和藥物交付合作夥伴取得商業成功的能力，包括他們在交付過程中使用公司的產品和服務療法；公司對支出、未來收入、資本需求以及額外融資的可用性和需求的預期、預測和估計；公司獲得額外資金以支持其研發計劃的能力；公司管理業務增長的能力；公司吸引和留住關鍵員工的能力；以及新產品的研究、開發和監管批准所固有的風險。有關這些因素以及可能影響公司實際業績的其他因素的更多詳細信息，請參閱公司向美國證券交易委員會提交的截至2023年12月31日止年度的10-K表年度報告的 “風險因素” 部分，以及公司打算在2024年5月15日當天或之前向美國證券交易委員會提交的截至2024年3月31日的三個月的10-Q表季度報告。公司不承擔任何更新這些前瞻性陳述的義務。
| CLEARPOINT NEURO, INC. Consolidated Statements of Operations (Unaudited) (in thousands, except for share and per share data) | |||||||
| For The Three Months Ended March 31, | |||||||
| 2024 | 2023 | ||||||
| Revenue: | |||||||
| Product revenue | $ | 3,635 | $ | 2,630 | |||
| Service and other revenue | 4,004 | 2,803 | |||||
| Total revenue | 7,639 | 5,433 | |||||
| Cost of revenue | 3,114 | 2,231 | |||||
| Gross profit | 4,525 | 3,202 | |||||
| Research and development costs | 2,625 | 3,023 | |||||
| Sales and marketing expenses | 3,290 | 2,933 | |||||
| General and administrative expenses | 2,841 | 2,958 | |||||
| Operating loss | (4,231) | (5,712) | |||||
| Other expense: | |||||||
| Other expense, net | (26) | (11) | |||||
| Interest income, net | 111 | 114 | |||||
| Net loss | $ | (4,146) | $ | (5,609) | |||
| Net loss per share attributable to common stockholders: | |||||||
| Basic and diluted | $ | (0.16) | $ | (0.23) | |||
| Weighted average shares used in computing net loss per share: | |||||||
| Basic and diluted | 25,452,096 | 24,583,163 | |||||
| CLEARPOINT NEURO, INC. 合併運營報表 （未經審計） （以千計，股票和每股數據除外） | |||||||
| 在結束的三個月中 3月31日 | |||||||
| 2024 | 2023 | ||||||
| 收入： | |||||||
| 產品收入 | $ | 3,635 | $ | 2,630 | |||
| 服務和其他收入 | 4,004 | 2,803 | |||||
| 總收入 | 7,639 | 5,433 | |||||
| 收入成本 | 3,114 | 2,231 | |||||
| 毛利 | 4,525 | 3,202 | |||||
| 研究和開發成本 | 2,625 | 3,023 | |||||
| 銷售和營銷費用 | 3,290 | 2,933 | |||||
| 一般和管理費用 | 2,841 | 2,958 | |||||
| 營業虧損 | (4,231) | (5,712) | |||||
| 其他費用： | |||||||
| 其他費用，淨額 | (26) | (11) | |||||
| 淨利息收入 | 111 | 114 | |||||
| 淨虧損 | $ | (4,146) | $ | (5,609) | |||
| 歸屬於普通股股東的每股淨虧損： | |||||||
| 基本款和稀釋版 | $ | (0.16) | $ | (0.23) | |||
| 用於計算每股淨虧損的加權平均股數： | |||||||
| 基本款和稀釋版 | 25,452,096 | 24,583,163 | |||||
| CLEARPOINT NEURO, INC. Consolidated Balance Sheets (in thousands, except for share and per share data) | |||||||
| March 31, 2024 | December 31, 2023 | ||||||
| (Unaudited) | |||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 35,353 | $ | 23,140 | |||
| Accounts receivable, net | 2,511 | 3,211 | |||||
| Inventory, net | 7,960 | 7,911 | |||||
| Prepaid expenses and other current assets | 1,746 | 1,910 | |||||
| Total current assets | 47,570 | 36,172 | |||||
| Property and equipment, net | 1,347 | 1,389 | |||||
| Operating lease, right-of-use assets | 3,447 | 3,564 | |||||
| Software license inventory | 237 | 386 | |||||
| Licensing rights | 887 | 1,041 | |||||
| Other assets | 149 | 109 | |||||
| Total assets | $ | 53,637 | $ | 42,661 | |||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 844 | $ | 393 | |||
| Accrued compensation | 1,634 | 2,947 | |||||
| Other accrued liabilities | 986 | 1,053 | |||||
| Operating lease liabilities, current portion | 497 | 424 | |||||
| Deferred product and service revenue, current portion | 1,232 | 2,613 | |||||
| 2020 senior secured convertible note payable, net | 9,964 | — | |||||
| Total current liabilities | 15,157 | 7,430 | |||||
| Operating lease liabilities, net of current portion | 3,438 | 3,568 | |||||
| Deferred product and service revenue, net of current portion | 458 | 541 | |||||
| 2020 senior secured convertible note payable, net | — | 9,949 | |||||
| Total liabilities | 19,053 | 21,488 | |||||
| Commitments and contingencies | |||||||
| Stockholders' equity: | |||||||
| Preferred stock, $0.01 par value; 25,000,000 shares authorized; none issued and outstanding at March 31, 2024 and December 31, 2023 | — | — | |||||
| Common stock, $0.01 par value; 90,000,000 shares authorized at March 31, 2024 and December 31, 2023; 27,416,345 shares issued and outstanding at March 31, 2024; and 24,652,729 issued and outstanding at December 31, 2023 | 274 | 247 | |||||
| Additional paid-in capital | 210,912 | 193,382 | |||||
| Accumulated deficit | (176,602) | (172,456) | |||||
| Total stockholders' equity | 34,584 | 21,173 | |||||
| Total liabilities and stockholders' equity | $ | 53,637 | $ | 42,661 | |||
| CLEARPOINT NEURO, INC. 合併資產負債表 （以千計，股票和每股數據除外） | |||||||
| 三月三十一日 2024 | 12月31日 2023 | ||||||
| （未經審計） | |||||||
| 資產 | |||||||
| 流動資產： | |||||||
| 現金和現金等價物 | $ | 35,353 | $ | 23,140 | |||
| 應收賬款，淨額 | 2,511 | 3,211 | |||||
| 庫存，淨額 | 7,960 | 7,911 | |||||
| 預付費用和其他流動資產 | 1,746 | 1,910 | |||||
| 流動資產總額 | 47,570 | 36,172 | |||||
| 財產和設備，淨額 | 1,347 | 1,389 | |||||
| 經營租賃、使用權資產 | 3,447 | 3,564 | |||||
| 軟件許可證清單 | 237 | 386 | |||||
| 許可權 | 887 | 1,041 | |||||
| 其他資產 | 149 | 109 | |||||
| 總資產 | $ | 53,637 | $ | 42,661 | |||
| 負債和股東權益 | |||||||
| 流動負債： | |||||||
| 應付賬款 | $ | 844 | $ | 393 | |||
| 應計補償 | 1,634 | 2,947 | |||||
| 其他應計負債 | 986 | 1,053 | |||||
| 經營租賃負債，流動部分 | 497 | 424 | |||||
| 遞延產品和服務收入，當期部分 | 1,232 | 2,613 | |||||
| 2020年優先有擔保可轉換票據應付票據，淨額 | 9,964 | — | |||||
| 流動負債總額 | 15,157 | 7,430 | |||||
| 經營租賃負債，扣除流動部分 | 3,438 | 3,568 | |||||
| 遞延產品和服務收入，扣除當期部分 | 458 | 541 | |||||
| 2020年優先有擔保可轉換票據應付票據，淨額 | — | 9,949 | |||||
| 負債總額 | 19,053 | 21,488 | |||||
| 承付款和意外開支 | |||||||
| 股東權益： | |||||||
| 優先股，面值0.01美元；授權2500萬股；截至2024年3月31日和2023年12月31日，未發行和流通股票 | — | — | |||||
| 普通股，面值0.01美元；截至2024年3月31日和2023年12月31日授權的9,000,000股股票；截至2024年3月31日已發行和流通的27,416,345股股票；截至2023年12月31日已發行和流通的24,652,729股 | 274 | 247 | |||||
| 額外的實收資本 | 210,912 | 193,382 | |||||
| 累計赤字 | (176,602) | (172,456) | |||||
| 股東權益總額 | 34,584 | 21,173 | |||||
| 負債和股東權益總額 | $ | 53,637 | $ | 42,661 | |||
| CLEARPOINT NEURO, INC. Consolidated Statements of Cash Flows (Unaudited) (in thousands) | |||||||
| For The Three Months Ended March 31, | |||||||
| 2024 | 2023 | ||||||
| Cash flows from operating activities: | |||||||
| Net loss | $ | (4,146) | $ | (5,609) | |||
| Adjustments to reconcile net loss to net cash flows from operating activities: | |||||||
| Allowance for credit losses (recoveries) | (146) | 171 | |||||
| Depreciation and amortization | 243 | 129 | |||||
| Share-based compensation | 1,504 | 1,307 | |||||
| Amortization of debt issuance costs and original issue discounts | 15 | 14 | |||||
| Amortization of lease right-of-use, net of accretion in lease liabilities | 231 | 142 | |||||
| Accretion of discounts on short-term investments | — | (69) | |||||
| Increase (decrease) in cash resulting from changes in: | |||||||
| Accounts receivable | 846 | (184) | |||||
| Inventory, net | 53 | (578) | |||||
| Prepaid expenses and other current assets | 165 | (42) | |||||
| Other assets | (39) | — | |||||
| Accounts payable and accrued expenses | (931) | (959) | |||||
| Lease liabilities | (171) | (146) | |||||
| Deferred revenue | (1,464) | 144 | |||||
| Net cash flows from operating activities | (3,840) | (5,680) | |||||
| Cash flows from investing activities: | |||||||
| Purchases of property and equipment | — | (138) | |||||
| Net cash flows from investing activities | — | (138) | |||||
| Cash flows from financing activities: | |||||||
| Proceeds from public offering of common stock, net of offering costs | 16,183 | — | |||||
| Proceeds from stock option exercises | 21 | — | |||||
| Payments for taxes related to net share settlement of equity awards | (151) | (5) | |||||
| Net cash flows from financing activities | 16,053 | (5) | |||||
| Net change in cash and cash equivalents | 12,213 | (5,823) | |||||
| Cash and cash equivalents, beginning of period | 23,140 | 27,615 | |||||
| Cash and cash equivalents, end of period | $ | 35,353 | $ | 21,792 | |||
| SUPPLEMENTAL CASH FLOW INFORMATION | |||||||
| Cash paid for: | |||||||
| Income taxes | $ | — | $ | — | |||
| Interest | $ | 185 | $ | 179 | |||
| CLEARPOINT NEURO, INC. 合併現金流量表 （未經審計） （以千計） | |||||||
| 在結束的三個月中 3月31日 | |||||||
| 2024 | 2023 | ||||||
| 來自經營活動的現金流： | |||||||
| 淨虧損 | $ | (4,146) | $ | (5,609) | |||
| 爲協調淨虧損與經營活動產生的淨現金流而進行的調整： | |||||||
| 信貸損失備抵金（追回款） | (146) | 171 | |||||
| 折舊和攤銷 | 243 | 129 | |||||
| 基於股份的薪酬 | 1,504 | 1,307 | |||||
| 債券發行成本和原始發行折扣的攤銷 | 15 | 14 | |||||
| 租賃使用權的攤銷，扣除租賃負債的增加 | 231 | 142 | |||||
| 增加短期投資折扣 | — | (69) | |||||
| 以下變動導致的現金增加（減少）： | |||||||
| 應收賬款 | 846 | (184) | |||||
| 庫存，淨額 | 53 | (578) | |||||
| 預付費用和其他流動資產 | 165 | (42) | |||||
| 其他資產 | (39) | — | |||||
| 應付賬款和應計費用 | (931) | (959) | |||||
| 租賃負債 | (171) | (146) | |||||
| 遞延收入 | (1,464) | 144 | |||||
| 來自經營活動的淨現金流量 | (3,840) | (5,680) | |||||
| 來自投資活動的現金流： | |||||||
| 購買財產和設備 | — | (138) | |||||
| 來自投資活動的淨現金流量 | — | (138) | |||||
| 來自融資活動的現金流： | |||||||
| 公開發行普通股的收益，扣除發行成本 | 16,183 | — | |||||
| 股票期權行使的收益 | 21 | — | |||||
| 支付與股權獎勵淨股結算相關的稅款 | (151) | (5) | |||||
| 來自融資活動的淨現金流量 | 16,053 | (5) | |||||
| 現金和現金等價物的淨變化 | 12,213 | (5,823) | |||||
| 現金和現金等價物，期初 | 23,140 | 27,615 | |||||
| 現金和現金等價物，期末 | $ | 35,353 | $ | 21,792 | |||
| 補充現金流信息 | |||||||
| 已支付的現金用於： | |||||||
| 所得稅 | $ | — | $ | — | |||
| 利息 | $ | 185 | $ | 179 | |||
Contact: Media Contact: Jacqueline Keller, Vice President of Marketing (888) 287-9109 ext. 4 info@clearpointneuro.com Investor Relations: Danilo D'Alessandro, Chief Financial Officer (888) 287-9109 ext. 3 ir@clearpointneuro.com
聯繫人：媒體聯繫人：傑奎琳·凱勒，營銷副總裁 (888) 287-9109 分機 4 info@clearpointneuro.com 投資者關係：達尼洛·達萊桑德羅，首席財務官 (888) 287-9109 分機 3 ir@clearpointneuro.com
Released May 7, 2024
2024 年 5 月 7 日發佈
譯文內容由第三人軟體翻譯。